Previous studies have found that aspirin intake can reduce the risk of colorectal carcinogenesis.
However, data are not sufficient for firm recommendations.
In this study, researchers from France evaluated 272 patients with a history of colorectal adenomas.
Patients were randomly assigned to receive daily lysine acetylsalicylate, either 160 or 300 mg per day, or placebo for 4 years.
The team set the primary end points as adenoma recurrence after 1 and 4 years.
|At least 1 adenoma was found in 30% of the aspirin group, compared with 41% of the placebo group.|
This study presents the results of colonoscopy after 1 year.
There were 238 patients who completed the year 1 colonoscopy.
The investigators found that at least 1 adenoma was observed in 30% of the aspirin group and in 41% of the placebo group (relative risk = 0.73).
At least 1 adenoma greater than 5 mm in diameter was detected in 10% of the aspirin group and 23% of the placebo group. Furthermore, adenomas greater than 10 mm were found in 1% of the aspirin group and 6% of the placebo group.
Using stepwise regression the team identified several independent factors associated with lower adenoma recurrence. These factors included aspirin treatment, absence of personal history of adenoma before the entry colonoscopy, and initial adenomatous polyp burden less than 10 mm.
Dr Robert Benamouzig's team concluded, "Daily soluble aspirin is associated with a reduction in the risk for recurrent adenomas found at colonoscopy 1 year after starting treatment".